These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 27378659)

  • 1. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
    Gori M; Senni M
    Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
    Sible AM; Nawarskas JJ; Alajajian D; Anderson JR
    Cardiol Rev; 2016; 24(1):41-7. PubMed ID: 26466333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
    Voors AA; Gori M; Liu LC; Claggett B; Zile MR; Pieske B; McMurray JJ; Packer M; Shi V; Lefkowitz MP; Solomon SD;
    Eur J Heart Fail; 2015 May; 17(5):510-7. PubMed ID: 25657064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
    King JB; Bress AP; Reese AD; Munger MA
    Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Vaduganathan M; Desai AS
    Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
    Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LCZ696 : a new paradigm for the treatment of heart failure?
    Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
    Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
    Mills J; Vardeny O
    Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
    Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
    Braunwald E
    J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O; Tacheny T; Solomon SD
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.